Cancer Clinical Trials
This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Advanced Colon Cancer
Trial Name: : A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.
Protocol ID: ECOG 7208
Patient must not have a known allergy to any of the treatment components.
Enrollment: • About 140 people will take part in this study at several medical centers in the United States and Canada.
Taking part in this study may or may not be of direct medical benefit to you. Possible benefits are shrinkage of your tumor, improvement in your symptoms related to your cancer and prolonged survival. We hope the information learned from this study will benefit other patients with colorectal cancer in the future.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.
Created: Jun 3, 2011
Updated: May 21, 2014